Scholar Rock Q1 net loss $39.4M; Phase 3 SMA trial enrollment on track for 2023

Scholar Rock Holding Corp

2023-Q1 EPS reported -$0.49

Net loss of $39.4M ($0.49 per share) vs $8.0M loss in prior year; revenue $0 vs $33.2M.
Cash, equivalents & marketable securities $275M as of March 31, 2023, funding into 2025.
Phase 3 SAPPHIRE trial for apitegromab in SMA enrollment completion expected in 2023, top-line data in 2024.
Phase 1 DRAGON trial for SRK-181 biomarker and clinical update planned for H2 2023.
Richard Brudnick appointed to Board of Directors in April 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Scholar Rock Holding Corp reported the quarter ended March 31, 2023 results: revenue $0, net income net loss was $39.4 million, EPS $0.49 per share.

Period: the quarter ended March 31, 2023
Revenue: $0
Net income: net loss was $39.4 million
EPS: $0.49 per share
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2023, net loss was $39.4 million or $0.49 per share compared to a net loss of $8.0 million or $0.21 per share for the quarter ended March 31, 2022. Revenue was $0 for the quarter ended March 31, 2023, compared to $33.2 million for the quarter ended March 31, 2022.

View on SEC.gov

Browse all earnings releases →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001157523-23-000777

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.